Global Controlled Drug Delivery Market & Controlled Drug Delivery Clinical Trial Outlook 2022

With significant paradigm shifts in drug discovery and development, the industry is also gearing up to adopt alternative drug delivery strategies in order to further facilitate drug development. Opportunities have significantly increased in the last few years. Pharmaceutical companies are collaborating with drug delivery firms to effectively target patient concerns. Many different drug delivery systems have been designed and evaluated, and a large number of strategies for site-specific drug targeting to pathological tissues have been explored.

Incorporating an existing medicine into a new drug delivery system can significantly improve its performance in terms of efficacy, safety, and improved patient compliance. The need for delivering drugs to patients efficiently and with fewer side effects has prompted pharmaceutical companies to engage in the development of new drug delivery systems.

Advantages of advanced drug delivery systems over traditional systems are the ability to deliver a drug more selectively to a specific site; easier, more accurate, less frequent dosing; decreased variability in systemic drug concentrations; absorption that is more consistent with the site and mechanism of action; and reductions in toxic metabolites. Providing control over the drug delivery can be the most important factor at times when traditional oral or injectable drug formulations cannot be used.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-controlled-drug-delivery-market-and-clinical-trial-outlook-2022.php

Report Table of Contents

1 Drug Delivery: An Advancing Trajectory
1.1 Preface Towards Drug Delivery
1.2 Idealism of Drug Delivery System

2. Introduction to Controlled Drug Delivery
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery

3. Evolution of Controlled Drug Delivery
3.1 First Generation
3.2 Second Generation

4. Fundamentals of Controlled Drug Delivery
4.1 Prerequisites of Controlled Delivery
4.2 Rationale for Controlled Drug Delivery

5. Mechanism of Controlled Drug Release
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System

6. Cataloging of Controlled Drug Delivery
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes

7. Approaches for Controlled Drug Delivery
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication

9. Application of Controlled Drug Delivery
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections

10. Drug Designing for Controlled Delivery
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release

11. Market Inclinations
11.1 Market over Routes of Administration
11.2 Market over Approaches

12. Global Controlled Drug Delivery Market Dynamics
12.1 Accelerative Parameters
12.2 Challenges

13. Global Controlled Drug Delivery Market Future Outlook
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities

14. Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Controlled Release Clinical Insight by Company, Indication and Phase

16. Competitive Landscape
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.